{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095097","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.220753+00:00","generated_at":"2026-05-31T10:01:14.359973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atossa reports $79.5M cash, no debt; EVANGELINE Phase 2 40mg cohort shows 100% disease control rate","bullets":["Ended Q2 2024 with $79.5M cash and cash equivalents, no debt; interest income $1.1M in Q2.","Total operating expenses $7.1M in Q2 2024 vs $7.8M in Q2 2023, down 9% YoY.","Phase 2 EVANGELINE 40mg cohort achieved 100% disease control rate at 24 weeks for ER+/HER2- breast cancer.","Completed enrollment in EVANGELINE 80mg PK run-in cohort and dosing in Phase 2 Karisma-Endoxifen trial (240 patients).","Appointed Heather Rees as CFO; joined Russell 3000 Index effective June 28, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095097","json":"https://secwatch.observer/filing/0000950170-24-095097.json","markdown":"https://secwatch.observer/filing/0000950170-24-095097.md","text":"https://secwatch.observer/filing/0000950170-24-095097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024095097/0000950170-24-095097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024095097/atos-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:01:14.359973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}